Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by smush74on Jan 13, 2015 11:33am
107 Views
Post# 23313562

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:come on 25 cents otc

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:come on 25 cents otc
Thanks for the comments and input. There really isn't much in common with SDI, not to mention that they just did a 25-1 reverse split which shot up their SP. The only commonality between them is they have cartridges to clean the blood. SDI is strickly going after sepsis they as of now are going in a more general path. They are not even at Phase I trial yet.

When I made my comments was more reffering to the partnership deals they have for their products (universities, DoD other branches of government) to finance the research, SDI on the other hand is going it alone and staying focussed on one area unlike them who are trying a cartiridge for everything and, anything they do is immediately released whether relevant or not.

My opinion both still have potential just depends who grabs some big pharma's eyes. I believe the major reason they get more exposure is they are US based but that can change as more info tricklees out.

Don't advocate one better than the other, just two different business models. But this is a SDI board so I will refrain for posting another company here.
Bullboard Posts